DEA Makes Cannabidiol Epilepsy Treatment Less Restrictive

Epidiolex was approved to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—in patients aged 2 years and older.

The Drug Enforcement Agency (DEA) is placing Epidiolex in Schedule V, the least restrictive schedule of the Controlled Substances Act.1 The drug is an oral solution containing cannabidiol (CBD), a chemical constituent of the cannabis plant, and it is expected to arrive on the market within 6 weeks.2

Previously classified as Schedule I,3 Epidiolex was approved in June to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome (LGS)—in patients aged 2 years and older.1-2 Manufactured by GW Pharmaceuticals and its US subsidiary Greenwich Biosciences, Epidiolex was the first product containing a purified drug substance derived from marijuana that the FDA approved for medical use.

CBD does not cause intoxication or the euphoria that comes from tetrahydrocannabinol, the primary psychoactive component of marijuana.3 Thursday’s announcement by the DEA marked the “final step” of the regulatory process for Epidiolex.

The placement of Epidiolex in Schedule V allows the company to move forward with making the product available to the market, according to Justin Gover, chief executive officer of GW Pharmaceuticals.2

“We are pleased that the DEA has placed Epidiolex in the lowest-restriction schedule, because it will help ensure that patients with LGS and Dravet syndrome, 2 of the most debilitating forms of epilepsy, can access this important new treatment option through their physicians,” he said in a statement.2 “We know there is excitement for a standardized version of cannabidiol that has undergone the rigor of controlled clinical trials and been approved by the FDA.”

Prior to receiving FDA approval, the Epidiolex clinical development program included 3 randomized, controlled Phase 3 clinical trials and an open-label extension study. The Phase 3 studies showed that Epidiolex added to other antiepileptic therapies, significantly reducing the frequency of seizures in patients with Dravet syndrome and LGS.4

“Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients,” FDA Commissioner Scott Gottlieb said in a statement.3 “Because of the adequate and well-controlled clinical studies that supported this approval, prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes."

Click to continue reading on Pharmacy Times.